Comparative Effectiveness of SGLT2 Inhibitors and GLP-1 Receptor Agonists in Preventing Alzheimer's Disease, Vascular Dementia, and Other Dementia Types Among Patients with Type 2 Diabetes

Diabetes & Metabolism, Год журнала: 2025, Номер unknown, С. 101623 - 101623

Опубликована: Фев. 1, 2025

Язык: Английский

---

Use of sodium‐glucose cotransporter‐2 inhibitors and risk of dementia: A population‐based cohort study

Diabetes Obesity and Metabolism, Год журнала: 2025, Номер unknown

Опубликована: Фев. 10, 2025

The effects of sodium-glucose co-transporter 2 inhibitors (SGLT-2i) on dementia risk have not been assessed in the Chinese population. We aimed to assess association between use SGLT-2i and incidence a mainland A target trial vs. dipeptidyl peptidase 4 (DPP-4i) was emulated, with cohorts type diabetes mellitus patients who were new users or DPP-4i being assembled using Yinzhou Regional Health Care Database. Inverse probability treatment weighting (IPTW) applied control potential confounding, Cox model used estimate hazard ratio (HR) incident dementia. final cohort included 47 335 SGLT-2i. In primary analysis, 500.2 347.5 per 100 000 person-years SGLT-2i, respectively. associated reduced after adjusting for confounding IPTW, an HR 0.74 (95% CI, 0.60-0.93). results generally consistent various subgroup analyses sensitivity analyses. is decreased study population China.

Язык: Английский

---

Challenges, current innovations, and opportunities for managing type 2 diabetes in frail older adults: a position paper of the European Geriatric Medicine Society (EuGMS)—Special Interest Group in Diabetes

European Geriatric Medicine, Год журнала: 2025, Номер unknown

Опубликована: Фев. 27, 2025

This position paper aims to address the challenges of managing type 2 diabetes mellitus (T2DM) in frail older adults, a diverse and growing demographic with significant variability health status. The primary research questions are: How can frailty assessment be effectively integrated into care? What strategies optimize glycaemic control outcomes for adults? innovative tools technologies, including artificial intelligence (AI), improve management this population? uses 5 I's framework (Identification, Innovation, Individualization, Integration, Intelligence) integrate care, proposing such as tools, novel therapies, digital AI systems. It also examines metabolic heterogeneity, highlighting anorexic-malnourished sarcopenic-obese phenotypes. proposed highlights importance tailoring targets levels, prioritizing quality life, minimizing treatment burden. Strategies leveraging are emphasized their potential enhance personalized care. distinct needs two phenotypes outlined, specific recommendations each group. calls holistic, patient-centered approach care ensuring equity access innovations life. need fill evidence gaps, refine healthcare integration better vulnerable

Язык: Английский

---

Glucagon-like peptide-1 receptor agonists for major neurocognitive disorders

Journal of Neurology Neurosurgery & Psychiatry, Год журнала: 2025, Номер unknown, С. jnnp - 335593

Опубликована: Апрель 10, 2025

Disease-modifying treatments for major neurocognitive disorders, including Alzheimer’s disease, Parkinson’s disease and other cognitive deficits, are among the main unmet needs in modern medicine. Glucagon-like peptide-1 receptor agonists (GLP-1RAs), currently licensed treatment of type 2 diabetes mellitus obesity, offer a novel, multilayered mechanism intervention neurodegeneration through intermediate, aetiology-agnostic pathways, likely involving metabolic, inflammatory several relevant neurobiological processes. In vitro animal studies have revealed promising signals neuroprotection, with preliminary supportive evidence emerging from recent pharmacoepidemiological investigations clinical trials. this article, we comprehensively review that investigate impact GLP-1RAs on various aetiologies impairment dementia syndromes. Focusing human studies, highlight how brain energy homeostasis, neurogenesis, synaptic functioning, neuroinflammation cellular stress responses, pathological protein aggregates, proteostasis, cerebrovascular system blood-brain barrier dynamics may underlie GLP-1RA putative neuroprotective effects. We then report appraise observational investigations, trials pooled analyses. Finally, discuss current challenges perspectives ahead research implementation care people their individual penetrance potential, need response biomarkers stage-based indications, possible non-specific effects health, profile terms adverse events unwanted effects, lack long-term data efficacy safety, issues surrounding cost availability treatment.

Язык: Английский

---

Comparative study of SGLT2 inhibitors and metformin: evaluating first-line therapies for dementia prevention in type 2 diabetes

Diabetes & Metabolism, Год журнала: 2025, Номер unknown, С. 101655 - 101655

Опубликована: Апрель 1, 2025

Язык: Английский

---

The Role of Diabetes and SGLT2 Inhibitors in Cerebrovascular Diseases

Current Neurology and Neuroscience Reports, Год журнала: 2025, Номер 25(1)

Опубликована: Май 24, 2025

Язык: Английский

---

Comparative Effectiveness of Sodium-Glucose Cotransporter-2 Inhibitors and Glucagon-Like Peptide-1 Receptor Agonists for Dementia Risk: A Real-World Study

Опубликована: Янв. 1, 2024

Язык: Английский

---